Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARRY S OJEAS

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1528051042
CMS profile
23333
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,682.65

157 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,682.65 157

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARRY S OJEAS

NPI 1528051042 · CMS profile ID 23333

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528051042?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARRY S OJEAS, NPI 1528051042, CMS profile ID 23333. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528051042?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). HARRY S OJEAS, NPI 1528051042, CMS profile ID 23333. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528051042?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
HARRY S OJEAS, NPI 1528051042, CMS profile ID 23333, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1528051042?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

157 matching records · $2,682.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 157 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 157.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.3905/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959797749 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.4205/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955758721 CMS
Gilead Sciences, Inc. $17.9405/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510181 CMS
Celgene Corporation $14.1005/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932560587 CMS
ABBVIE INC. $17.0304/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281657 CMS
ABBVIE INC. $20.2704/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281655 CMS
ABBVIE INC. $28.7404/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281653 CMS
Braintree Laboratories, Inc. $23.7804/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898419739 CMS
Celgene Corporation $15.0604/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932560505 CMS
Gilead Sciences, Inc. $24.8204/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510193 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.4404/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955758717 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.0304/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955758711 CMS
ABBVIE INC. $9.6004/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281649 CMS
ABBVIE INC. $22.5104/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281651 CMS
Nestle HealthCare Nutrition Inc. $29.8204/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902790717 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.7703/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955758707 CMS
ABBVIE INC. $27.1503/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281647 CMS
Celgene Corporation $21.9503/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932560503 CMS
Gilead Sciences, Inc. $15.9103/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510173 CMS
Gilead Sciences, Inc. $25.8903/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510197 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.0803/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959854259 CMS
ABBVIE INC. $18.1903/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281645 CMS
Gilead Sciences, Inc. $1.7603/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510151 CMS
Gilead Sciences, Inc. $4.3403/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510163 CMS
Celgene Corporation $12.2003/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932560499 CMS
RedHill Biopharma Inc. $4.3803/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902944133 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.8603/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960034445 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.2903/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955758703 CMS
ABBVIE INC. $29.2103/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281643 CMS
Evoke Pharma, Inc. $19.4003/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913793623 CMS
ABBVIE INC. $14.6102/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281641 CMS
INTERCEPT PHARMACEUTICALS, INC. $15.8502/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951528159 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.9502/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960033197 CMS
ABBVIE INC. $21.1802/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281639 CMS
Celgene Corporation $14.9102/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932560497 CMS
Nestle HealthCare Nutrition Inc. $19.3202/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902790715 CMS
Ironwood Pharmaceuticals, Inc $22.0802/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957934165 CMS
ABBVIE INC. $29.4502/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281637 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.3802/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959704771 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.6202/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959870261 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.6802/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959976729 CMS
Gilead Sciences, Inc. $15.2002/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510169 CMS
Evoke Pharma, Inc. $17.2802/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913792873 CMS
Gilead Sciences, Inc. $19.7201/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510185 CMS
Janssen Biotech, Inc. $16.6001/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886627587 CMS
Celgene Corporation $21.4401/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932560495 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.0901/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955758697 CMS
ABBVIE INC. $21.6601/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891281635 CMS
Gilead Sciences, Inc. $1.5701/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510147 CMS
RedHill Biopharma Inc. $9.9001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902938655 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.87 166
PY2020 $1,166.59 81
PY2021 $2,143.95 143
PY2022 $2,682.65 157
PY2023 $2,886.73 159
PY2024 $673.57 38
PY2025 $2,662.37 131

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $67,302.85 21
PY2024 Principal investigator $236,207.10 36
PY2023 Principal investigator $130,540.05 51
PY2022 Principal investigator $118,975.52 50
PY2021 Principal investigator $132,423.40 63
PY2020 Principal investigator $410,531.57 160
PY2019 Principal investigator $416,290.36 130

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,992.55 12/04/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202528930
Principal investigator 1 ABBVIE INC. $1,891.95 11/04/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202520581
Principal investigator 1 ABBVIE INC. $5,701.60 11/04/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202520609
Principal investigator 1 ABBVIE INC. $1,817.40 10/09/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202515447
Principal investigator 1 ABBVIE INC. $254.50 10/09/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202515449
Principal investigator 1 ABBVIE INC. $8,889.85 09/03/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202507247
Principal investigator 1 ABBVIE INC. $341.55 09/03/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202507249
Principal investigator 1 ABBVIE INC. $1,276.70 08/05/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202501552
Principal investigator 1 ABBVIE INC. $1,382.95 08/05/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202501678
Principal investigator 1 ABBVIE INC. $4,135.60 07/02/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202495641
Principal investigator 1 ABBVIE INC. $1,790.75 05/06/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202481829
Principal investigator 1 ABBVIE INC. $1,619.60 05/06/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202481837
Principal investigator 1 ABBVIE INC. $9,623.40 05/06/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202481847
Principal investigator 1 ABBVIE INC. $1,678.60 04/03/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202473261
Principal investigator 1 ABBVIE INC. $452.00 04/03/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202473265
Principal investigator 1 ABBVIE INC. $9,342.20 03/06/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202458458
Principal investigator 1 ABBVIE INC. $1,276.70 02/05/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202445321
Principal investigator 1 ABBVIE INC. $5,627.40 02/05/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202445326
Principal investigator 1 ABBVIE INC. $1,705.25 02/05/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202445330
Principal investigator 1 ABBVIE INC. $2,226.90 01/02/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202435172
Principal investigator 1 ABBVIE INC. $275.40 01/02/2025 Non-covered Recipient Entity
VILO RESEARCH GROUP INC
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202435657

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $5,567.46 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $5,567.46 1
PY2022 Amount invested $349.70 1
PY2022 Value of interest $349.70 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

3 records · PY2022–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $5,567.46 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124819836
PY2023 GastroGPO, LLC $0.00 $5,567.46 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050730409
PY2022 GastroGPO, LLC $349.70 $349.70 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 955000819